Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Increase in Short Interest

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,500,000 shares, an increase of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is currently 2.6 days.

Analysts Set New Price Targets

A number of analysts recently issued reports on ADAP shares. StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. HC Wainwright reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. Mizuho reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Finally, Guggenheim reduced their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $2.79.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Fullcircle Wealth LLC acquired a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at about $33,000. Vontobel Holding Ltd. boosted its stake in Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at approximately $95,000. Virtu Financial LLC boosted its stake in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the period. Finally, Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the period. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Down 1.7 %

NASDAQ:ADAP opened at $0.58 on Friday. The company’s 50 day moving average is $0.64 and its 200-day moving average is $0.90. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.05. The firm has a market cap of $148.38 million, a price-to-earnings ratio of -2.64 and a beta of 2.24.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.